The Research Institute of the McGill University Health Centre

8 articles about The Research Institute of the McGill University Health Centre

• MI4, Montreal’s powerhouse of infectious disease research, celebrates five years of innovation and philanthropy

  4/27/2023

  Though we cannot see them, microbes have had a profound effect on our lives, humanity and the world.

• InvestmentPitch Media Video Discusses Hemostemix and its $250,000 in Funding from McGill University Health Centre Foundation for Clinical Trial of ACP-01

  1/23/2023

  Hemostemix Inc. (TSXV:HEM) (OTCQB:HMTXF), an autologous stem cell therapy company, has received a $250,000 Letter of Commitment for funding from the McGill University Health Centre (MUHC) Foundation.

• New study will assess impact of COVID-19 vaccination on Canadians with immune-mediated inflammatory disease

  9/9/2021

  More than 7 million Canadians suffer from immune-mediated inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, psoriasis, and related conditions.

• Montreal Chest Institute Foundation and MUHC Foundation join forces to change the course of lives and medicine

  2/24/2021

  A merger and the launch of a $10 million dollar respiratory campaign, part of the McGill University Health Centre Foundation’s larger Dream Big campaign, will ensure the Montreal Chest Institute will continue as a world leader in respiratory care

• Reaching new heights by working together: Innovative industry partnership using artificial intelligence to improve survival rates of cancer diagnosed patients

  1/21/2021

  The McGill University Health Centre Foundation and MEDTEQ+ are proud to announce a new partnership with the Research Institute of the McGill University Health Centre, MIMs, and Caprion-HistoGeneX, respective leaders in cancer research, artificial intelligence, and precision medicine, to increase survival of stage IV colorectal cancer patients.

• Old drug, new therapy: RI-MUHC-sponsored phase III clinical trial ready to test repurposed dapsone to tone down lung inflammation caused by COVID-19

  9/2/2020

  Reformulated and patented version of well-known generic drug could prove to be a quick, safe and cost-effective way to accelerate recovery and prevent hospitalizations.

• CAE supports state-of-the-art healthcare training at the MUHC

  2/5/2020

  A global leader in training is helping to build Canada's best skilled team in healthcare

• PharmaNet, Inc. and The Research Institute of the McGill University Health Centre Announce the First Translational Medicine Unit In Canada

  9/15/2011